2017: The FDA approves a long-acting, once weekly GLP-1 RA injectable exenatide (Bydureon BCise)
GLP-1 receptor agonists and estrogen both influence lipid metabolism in adipose tissue, liver, and muscle but through converging protein kinase pathways
The observed weight regain following drug withdrawal reflects the underlying pathophysiology of energy homeostasis rather than therapeutic failure
Epilepsy and movement disorders: A severe deficiency caused by rare mutations in the PNPO enzyme can result in encephalopathy, epilepsy, and movement disorders from infancy
The Vital Pursuit products are said to be high in protein, good sources of fibre, and contain essential nutrients
Adjust protocols as needed based on progress and feedback